Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Barcode Labeling Increasing in Anticipation of Mandatory Use in 2021: MHLW Survey
The rate of barcode labeling of product codes for oral and topical drugs in dispensing package units (blister packs and ampules) rose sharply at the end of September 2015 compared to the previous year, the health ministry announced on September…
To read the full story
Related Article
- MHLW Issues Notification on Partial Revision of Rules for New Barcode Labeling to Be Required from April 2021
September 6, 2016
- Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
April 18, 2016
- Drug Makers, Distributors Won’t Set Interim Targets for Mandatory Barcode Labeling, but Keep Tabs on Progress
March 25, 2016
REGULATORY
- Japan Targets Global-Level Growth for Domestic Patented Drug Market
June 25, 2026
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Japan Diet Begins Deliberations on Immunization Act Revision
June 25, 2026
- Expert Calls for AMR Ecosystem to Boost Japan Antibiotic Innovation
June 25, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…